Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC)

L. Zelek (1) , P. Debourdeau , H. Bourgeois , J. P. Wagner , F. Brocard (2) , C. Lefeuvre-Plesse (3) , Bruno Chauffert (4, 5) , M. Leheurteur (6) , J-B. Bachet (7) , H. Simon , D. Mayeur , N. Jovenin , F. Scotte

1 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
2 Oncologie médicale [Polyclinique de Gentilly, Nancy]
3 CRLCC - CRLCC Eugène Marquis
4 CHU Amiens-Picardie
5 CHIMERE - CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516
6 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
7 CHU Pitié-Salpêtrière [AP-HP]

Domaines: Sciences du Vivant [q-bio]

L. Zelek, P. Debourdeau, H. Bourgeois, J. P. Wagner, F. Brocard, et al.. Single-dose NEPA versus 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with risk factors receiving moderately emetogenic chemotherapy (MEC). Annals of Oncology, 2021, 32 (5), pp.S1175. ⟨10.1016/j.annonc.2021.08.1644⟩. ⟨hal-03598658⟩